The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
复制标题
DOI：
10.1007/s13402-011-0052-6
复制
发表时间：
2012-02
期刊：
影响因子：
--
通讯作者：
Bart J
中科院分区：
文献类型：
--
作者：
Crane LM;Arts HJ;van Oosten M;Low PS;van der Zee AG;van Dam GM;Bart J
叶酸受体α (FR-α)已被确定为卵巢癌诊断和治疗的潜在靶点，基于其在浆液上皮性卵巢癌中的过表达。化疗对FR-α表达的影响可能对FR-α靶向药物在残余肿瘤组织中的适用性具有重要意义。本研究的目的是评估FR-α在卵巢癌中的表达，并评估FR-α的表达是否会因化疗而改变。采用组织微阵列（TMAs）免疫组化半定量评分法分析FR-α表达，该方法来自361例卵巢癌组织样本，其中210例浆液性癌和116例非浆液性癌（缺失35例）。浆液性癌样本包括28个原发手术和间歇减容手术组织的匹配样本，12个原发手术和复发性疾病手术组织的匹配样本。FR-α在81.8%的浆液性卵巢癌和39.9%的非浆液性癌中表达（p < 0.001）。在匹配的浆液性癌样本中，化疗后重要肿瘤组织FR-α表达无显著变化（p = 0.1）。FR-α表达不是无进展生存期（p = 0.8）或总生存期（p = 0.7）的预后指标。FR-α在绝大多数浆液性卵巢肿瘤中均有表达，但约50%的卵巢肿瘤呈弱表达。化疗并没有改变剩余重要肿瘤组织中的表达率，这表明叶酸靶向药物可能在化疗前后的卵巢癌治疗中占有一席之地。此外，FR-α状态不影响存活。
Folate receptor alpha (FR-α) has been identified as a potential target in ovarian cancer for diagnostic and therapeutic purposes, based on its overexpression in serous epithelial ovarian carcinoma. The effect of chemotherapy on FR-α expression may be important in the applicability of FR-α directed agents in the case of residual tumor tissue. The objective of this study was to assess FR-α expression in ovarian carcinoma and to evaluate whether FR-α expression is altered by chemotherapy. FR-α expression was analyzed by semi-quantitative scoring of immunohistochemical staining on tissue microarrays (TMAs) from a database containing 361 ovarian cancer tissue samples, of which 210 serous and 116 non-serous carcinoma (35 missing). Serous carcinoma samples included 28 matched samples with tissue from both primary surgery and interval debulking surgery, and 12 matched samples with tissue from both primary surgery and surgery for recurrent disease. FR-α expression was seen in 81.8% of serous ovarian cancers versus 39.9% of non-serous carcinomas (p < 0.001). In matched serous carcinoma samples, no significant change in FR-α expression in vital tumor tissue after chemotherapy was observed (p = 0.1). FR-α expression was not a prognostic marker of progression free survival (p = 0.8) or overall survival (p = 0.7). FR-α was expressed in the majority of serous ovarian tumors, although >50% of cases showed only weak expression. Chemotherapy did not alter expression rates in remaining vital tumor tissue, indicating that folate-targeted agents may have a place in the treatment for ovarian cancer, before as well as after chemotherapy. Furthermore, FR-α status did not influence survival.
登录
查看更多内容
在多中心研究中，影响卵巢癌p53表达的因素是临床结果的生物标志物。
影响因子：
8.8
作者：
de Graeff, P;Hall, J;Crijns, A P G;de Bock, G H;Paul, J;Oien, K A;ten Hoor, K A;de Jong, S;Hollema, H;Bartlett, J M S;Brown, R;van der Zee, A G J
通讯作者：
van der Zee, A G J
影响因子：
45.3
作者：
Winter, William E., III;Maxwell, G. Larry;McGuire, William P.
通讯作者：
McGuire, William P.
影响因子：
4.7
作者：
Kalli, Kimberly R.;Oberg, Ann L.;Hartmann, Lynn C.
通讯作者：
Hartmann, Lynn C.
影响因子：
4.7
作者：
Bagnoli, M;Canevari, S;Miotti, S
通讯作者：
Miotti, S
影响因子：
4.7
作者：
Leamon, CP;Parker, MA;Douglas, N
通讯作者：
Douglas, N